These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 8988734

  • 1. Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).
    Dreicer R, Propert KJ, Roth BJ, Einhorn LH, Loehrer PJ.
    Cancer; 1997 Jan 01; 79(1):110-4. PubMed ID: 8988734
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
    Kyriakakis Z, Dimopoulos MA, Kostakopoulos A, Karayiannis A, Sofras F, Zervas A, Giannopoulos A, Dimopoulos C.
    J Urol; 1997 Aug 01; 158(2):408-11. PubMed ID: 9224313
    [Abstract] [Full Text] [Related]

  • 3. The role of ifosfamide in the treatment of testicular and urothelial malignancies.
    Roth BJ.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 7):19-27. PubMed ID: 8711497
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma.
    Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ.
    J Clin Oncol; 1994 Nov 01; 12(11):2271-6. PubMed ID: 7525884
    [Abstract] [Full Text] [Related]

  • 5. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF.
    Urology; 2007 Feb 01; 69(2):255-9. PubMed ID: 17320659
    [Abstract] [Full Text] [Related]

  • 6. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, Herr H, Scher HI, Icasiano E, Higgins G.
    Cancer; 2000 Apr 01; 88(7):1671-8. PubMed ID: 10738226
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS.
    J Urol; 2007 Jan 01; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [Abstract] [Full Text] [Related]

  • 8. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ, Meyers FJ, Houston J, Lauder I.
    Semin Oncol; 1997 Oct 01; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [Abstract] [Full Text] [Related]

  • 9. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martín J, Martínez-Trufero J, de las Peñas R, Buesa JM, Spanish Group for Research on Sarcomas (GEIS).
    Cancer; 2004 Apr 01; 100(7):1498-506. PubMed ID: 15042685
    [Abstract] [Full Text] [Related]

  • 10. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY.
    Cancer; 1998 Jan 01; 82(1):134-40. PubMed ID: 9428489
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.
    Cancer; 2005 Oct 15; 104(8):1627-32. PubMed ID: 16138364
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
    Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ, Kaufman DS.
    J Clin Oncol; 2006 Jul 20; 24(21):3451-7. PubMed ID: 16849761
    [Abstract] [Full Text] [Related]

  • 13. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.
    Cancer J Sci Am; 1997 Jul 20; 3(5):297-302. PubMed ID: 9327154
    [Abstract] [Full Text] [Related]

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 20; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 15. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
    Mulatero C, McClaren BR, Mason M, Oliver RT, Gallagher CJ.
    Br J Cancer; 2000 Dec 20; 83(12):1612-6. PubMed ID: 11104554
    [Abstract] [Full Text] [Related]

  • 16. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G, Fei F, Mangioni C.
    Semin Oncol; 2000 Feb 20; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
    Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK.
    Cancer; 2002 Jul 15; 95(2):322-30. PubMed ID: 12124833
    [Abstract] [Full Text] [Related]

  • 18. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM, Rankin C, Taub RN, Balcerzak SP, Bhoopalam N, Chapman RA, Baker LH, Middleman EL, Antman KH.
    Cancer; 2003 Jul 15; 98(2):331-6. PubMed ID: 12872353
    [Abstract] [Full Text] [Related]

  • 19. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM, Glisson BS, Khuri FR, Hong WK, Lippman SM.
    Semin Oncol; 1998 Apr 15; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, Gebhardt M, Pratt C, Grier HE.
    J Clin Oncol; 2005 Jun 20; 23(18):4031-8. PubMed ID: 15767644
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.